Mizuho lowers Acadia Pharmaceuticals stock price target to $22 from $32

Investing.com - Mizuho has reduced its price target on Acadia Pharmaceuticals (NASDAQ:ACAD) to $22.00 from $32.00 while maintaining a Neutral rating on the stock. The stock currently trades at $25.13, near its 52-week high of $25.88, after posting impressive returns of over 60% in the past year.

The price target adjustment follows Acadia’s second-quarter 2025 results, which Mizuho noted fell short of consensus estimates when excluding the incremental impact of direct provider payments (DPPs) during the quarter.

Mizuho cited "execution missteps" as a key factor in its decision to lower estimates for Acadia’s adjusted EBITDA for the years 2025 through 2027.

The firm also expressed concerns about uncertainty regarding the ongoing impact of Medicaid Redeterminations and the One Big Beautiful Bill Act (OBBBA) on Acadia’s business performance.

Despite the significant 31% reduction in price target, Mizuho maintained its Neutral stance on Acadia Pharmaceuticals stock, indicating a cautious outlook while the company navigates these challenges.

In other recent news, Acadia Pharmaceuticals reported its second-quarter earnings, surpassing Wall Street expectations with an earnings per share of $0.16, compared to the forecasted $0.14. The company’s revenue reached $264.6 million, slightly ahead of the $262.44 million forecast. Acadia’s Nuplazid sales were reported at $168.5 million, aligning with consensus expectations, while Daybue sales reached $96.1 million, exceeding estimates. Following these results, management raised the low end of its fiscal year 2025 guidance for Nuplazid and reiterated guidance for Daybue.

In response to the solid earnings, Stifel raised its price target for Acadia Pharmaceuticals to $24 from $18, maintaining a Hold rating. Similarly, Mizuho increased its price target to $24 from $23, keeping a Neutral rating. Citizens JMP also raised its price target to $38 from $37, maintaining a Market Outperform rating. These developments highlight the company’s strong performance in the second quarter and its impact on analysts’ projections.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.